David Bearss is the founder of Halia Therapeutics. Halia Therapeutics has raised $78M in total funding. Based in Salt Lake City, Utah.
David Bearss is the Co-Founder, CEO, and President of Halia Therapeutics, a biotechnology company focused on chronic inflammation and aging therapies. He leads the company's clinical programs, including a Phase 2 trial for HT-6184 in myo plastic syndromes and a Phase 1 study for HT-4253 targeting neuroinflammation in Alzheimer's disease. Bearss was recognized by PharmaVoice as one of the 100 Standout Leaders in the Life Sciences Industry.
Full founder directory · Investor directory · Company funding database · Fundraising library